RAPT Therapeutics Receives the US FDA’s IND Clearance to Evaluate RPT904 for Food Allergy

Shots:The US FDA has granted IND clearance to initiate P-IIb (prestIgE) trial of RPT904 for the treatment of pts with IgE-mediated food allergy by the end of 2025The P-IIb (prestIgE) trial will assess RPT904 (SC; loading at Wk. 2, then Q8W or Q12W) vs PBO in 2 parts: In Part 1, ~100 pts with ≥1 food…

ByRidhi RastogiSeptember 30, 2025

INSIGHTS+

Know Your Investor: Deep Track Capital (June’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…

ByPrince GiriJune 5, 2025

RAPT Therapeutics Receives the US FDA’s IND Clearance to Evaluate RPT904 for Food Allergy

Know Your Investor: Deep Track Capital (June’25 Edition)

Contact US

OUR INFORMATION

FOLLOW US